Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics

Background: Dasatinib, nilotinib, and sorafenib are clinically proven tyrosine kinase inhibitors (TKIs) used for the treatment of leukemia and hepatocellular carcinoma. However, there is a growing concern regarding cardiotoxicity associated with their use. The impact of these TKIs on vascular smooth...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhazzani, Khalid, Almangour, Abdullah, Alsalem, Abdulaziz, Alqinyah, Mohammed, Alhamed, Abdullah S., Alhamami, Hussain N., Alanazi, Ahmed Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594443/
https://www.ncbi.nlm.nih.gov/pubmed/37873791
http://dx.doi.org/10.3390/diseases11040147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594443/
https://www.ncbi.nlm.nih.gov/pubmed/37873791
http://dx.doi.org/10.3390/diseases11040147

Ejemplares similares